Enhanced human tissue microdialysis using hydroxypropyl-ß-cyclodextrin as molecular carrier

PLoS One. 2013;8(4):e60628. doi: 10.1371/journal.pone.0060628. Epub 2013 Apr 5.

Abstract

Microdialysis sampling of lipophilic molecules in human tissues is challenging because protein binding and adhesion to the membrane limit recovery. Hydroxypropyl-ß-cyclodextrin (HP-ß-CD) forms complexes with hydrophobic molecules thereby improving microdialysis recovery of lipophilic molecules in vitro and in rodents. We tested the approach in human subjects. First, we determined HP-ß-CD influences on metabolite stability, delivery, and recovery in vitro. Then, we evaluated HP-ß-CD as microdialysis perfusion fluid supplement in 20 healthy volunteers. We placed 20 kDa microdialysis catheters in subcutaneous abdominal adipose tissue and in the vastus lateralis muscle. We perfused catheters with lactate free Ringer solution with or without 10% HP-ß-CD at flow rates of 0.3-2.0 µl/min. We assessed tissue metabolites, ultrafiltration effects, and blood flow. In both tissues, metabolite concentrations with Ringer+HP-ß-CD perfusate were equal or higher compared to Ringer alone. Addition of HP-ß-CD increased dialysate volume by 10%. Adverse local or systemic reactions to HP-ß-CD did not occur and analytical methods were not disturbed. HP-ß-CD addition allowed to measure interstitial anandamide concentrations, a highly lipophilic endogenous molecule. Our findings suggest that HP-ß-CD is a suitable supplement in clinical microdialysis to enhance recovery of lipophilic molecules from human interstitial fluid.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Hydroxypropyl-beta-cyclodextrin
  • Adipose Tissue / drug effects*
  • Adipose Tissue / metabolism*
  • Adult
  • Blood Circulation / drug effects
  • Endocannabinoids / metabolism
  • Ethanol / chemistry
  • Feasibility Studies
  • Female
  • Glucose / metabolism
  • Humans
  • Lipolysis / drug effects
  • Male
  • Microdialysis / methods*
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / metabolism*
  • beta-Cyclodextrins / adverse effects
  • beta-Cyclodextrins / pharmacology*

Substances

  • Endocannabinoids
  • beta-Cyclodextrins
  • 2-Hydroxypropyl-beta-cyclodextrin
  • Ethanol
  • Glucose

Grants and funding

The study was supported by the German Obesity Network of Competence (projects 01 Gl0830 and 01 Gl1122D) and the Commission of the European Communities (Collaborative Project ADAPT, Contract No. HEALTH-F2-2008-201100. Publication costs are funded by the support Program ‘open access publication’ of the Deutsche Forschungsgemeinschaft. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.